Coronavirus Vaccine And Its Timing: Bill Gates

The coronavirus pandemic is far from over even as companies tout milestones in the development of much-needed vaccines. Bill Gates believes a vaccine will not be available before the end of the year for use in America.

Coronavirus Vaccine Stalemate

According to the billionaire philanthropist, none of the vaccines is ready or likely to seek regulatory approval in the U.S. The earliest that people should expect a vaccine is early next year should things go well.

The sentiments come on the heels of Pfizer CEO Albert Bourla, reiterating that one of their three coronavirus vaccines is in the late stage of development. While it could be distributed before the end of the year. The same is dependent on it being found to be safe and effective. Moderna and AstraZeneca are the other drug makers believed to be in the late stages of testing.

Even as the U.S lags on the development and approval of a coronavirus vaccine, some countries claim to have made important milestones. Russia and China have already approved the emergency use of their vaccines, although they have been met with lots of skepticism from Western medical professionals.

COVID-19 Vaccine Need

A safe and effective coronavirus vaccine is highly needed to avert the shocks triggered by the pandemic. The global economy has already plunged into recession as key sectors of the economy struggle to bounce back to pre-corona levels.

The World Bank has already warned that poverty rates are poised to edge higher as the global economy continues to fall. The number of people leaving on less than $2 is on the rise, with 37 million people believed to be in extreme poverty. Unlike in the past, the downturn is not limited to poor countries. For instance, one in three Americans is in trouble paying bills.

In addition, the COVID-19 pandemic erased 25 years of progress in vaccines in 25 weeks. More and more people have been going without key lifesaving vaccines. The result is the potential spread of dangerous diseases.

By reading our website you agree to the terms of our disclaimer, which are subject to change at any time. Owners and affiliates are not registered or licensed in any jurisdiction whatsoever to provide financial advice or anything of an advisory nature. Always do your own research and/or consult with an investment professional before investing. Low priced stocks are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold us, our editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters, website, twitter, Facebook or chat. We do not advise any reader to take any specific action. Our releases are for informational and educational purposes only. Never invest purely based on our articles. Gains mentioned on our website, twitter, Facebook, and on our website may be based on EOD or intraday data. We may be compensated for the production, release, and awareness of this article. We will disclose any and all compensation on the article page. This publication and its owner never hold positions in the securities mentioned in our articles. Our information may contain Forward-Looking Statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site. The information in our disclaimers is subject to change at any time without notice. We are not held liable or responsible for the information in press releases issued by the companies discussed in these write-ups. Please do your own due diligence